Cargando…

Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients

SIMPLE SUMMARY: Rrisk assessment of microsatellite instability (MSI) and copy-number (CN)-low endometrial adenocarcinomas constitutes a major challenge. We aimed to identify tissue-based morphologic biomarkers that might help in the prognostic stratification, comprehensively analyzing one finding co...

Descripción completa

Detalles Bibliográficos
Autores principales: Stögbauer, Fabian, Geß, Barbara, Brambs, Christine, Lautizi, Manuela, Kacprowski, Tim, Ourailidis, Iordanis, Bronger, Holger, Kiechle, Marion, Noske, Aurelia, Keller, Gisela, Jesinghaus, Moritz, Poremba, Christopher, Weichert, Wilko, Boxberg, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416921/
https://www.ncbi.nlm.nih.gov/pubmed/37568650
http://dx.doi.org/10.3390/cancers15153832
_version_ 1785087893782396928
author Stögbauer, Fabian
Geß, Barbara
Brambs, Christine
Lautizi, Manuela
Kacprowski, Tim
Ourailidis, Iordanis
Bronger, Holger
Kiechle, Marion
Noske, Aurelia
Keller, Gisela
Jesinghaus, Moritz
Poremba, Christopher
Weichert, Wilko
Boxberg, Melanie
author_facet Stögbauer, Fabian
Geß, Barbara
Brambs, Christine
Lautizi, Manuela
Kacprowski, Tim
Ourailidis, Iordanis
Bronger, Holger
Kiechle, Marion
Noske, Aurelia
Keller, Gisela
Jesinghaus, Moritz
Poremba, Christopher
Weichert, Wilko
Boxberg, Melanie
author_sort Stögbauer, Fabian
collection PubMed
description SIMPLE SUMMARY: Rrisk assessment of microsatellite instability (MSI) and copy-number (CN)-low endometrial adenocarcinomas constitutes a major challenge. We aimed to identify tissue-based morphologic biomarkers that might help in the prognostic stratification, comprehensively analyzing one finding cohort (TCGA-UCEC) and two independent validation cohorts. Histomorphologic parameters (WHO grading, tumor budding (TB), tumor–stroma ratio, tumor-infiltrating lymphocytes (TIL), “microcystic, elongated, fragmented” (MELF) pattern) were analyzed. For each quantitative parameter, a two-tiered system was developed utilizing systematically determined cutoffs. In MSI tumors, TB (≥3 buds/high-power field) was detected to be an independent prognostic factor for inferior outcomes and lymph node metastases. The finding was confirmed in two validation cohorts. For CN-low tumors, solely WHO grading was independently prognostic with inferior outcomes for high-grade tumors. Therefore, we propose the utilization of TB and WHO-based grading, two tissue-based and easy-to-assess biomarkers, in MSI/CN-low endometrial carcinomas for improved clinical management. ABSTRACT: The molecular characterization of endometrial endometrioid adenocarcinomas has provided major advances in its prognostic stratification. However, risk assessment of microsatellite instability (MSI) and copy-number (CN)-low cases remains a challenge. Thus, we aimed to identify tissue-based morphologic biomarkers that might help in the prognostic stratification of these cases. Histomorphologic parameters (WHO grading, tumor budding (TB), tumor–stroma ratio (as a quantitative description of stromal desmoplasia), tumor-infiltrating lymphocytes (TIL), “microcystic, elongated, fragmented” (MELF) pattern) were analyzed in resection specimens of the TCGA-UCEC cohort (n = 228). For each quantitative parameter, a two-tiered system was developed utilizing systematically determined cutoffs. Associations with survival outcomes were calculated in univariate and multivariate analysis and validated in two independent cohorts. In MSI tumors, only TB remained an independent prognostic factor. TB (≥3 buds/high-power field) was associated with inferior outcomes and with lymph node metastases. The prognostic significance of TB was confirmed in two validation cohorts. For CN-low tumors, established grading defined by the WHO was independently prognostic with inferior outcomes for high-grade tumors. The evaluation of TB might help in identifying MSI-patients with unfavorable prognosis who, e.g., could benefit from lymphadenectomy. WHO-based grading facilitates independent prognostic stratification of CN-low endometrioid adenocarcinomas. Therefore, we propose the utilization of TB and WHO-based grading, two tissue-based and easy-to-assess biomarkers, in MSI/CN-low endometrial carcinomas for improved clinical management.
format Online
Article
Text
id pubmed-10416921
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104169212023-08-12 Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients Stögbauer, Fabian Geß, Barbara Brambs, Christine Lautizi, Manuela Kacprowski, Tim Ourailidis, Iordanis Bronger, Holger Kiechle, Marion Noske, Aurelia Keller, Gisela Jesinghaus, Moritz Poremba, Christopher Weichert, Wilko Boxberg, Melanie Cancers (Basel) Article SIMPLE SUMMARY: Rrisk assessment of microsatellite instability (MSI) and copy-number (CN)-low endometrial adenocarcinomas constitutes a major challenge. We aimed to identify tissue-based morphologic biomarkers that might help in the prognostic stratification, comprehensively analyzing one finding cohort (TCGA-UCEC) and two independent validation cohorts. Histomorphologic parameters (WHO grading, tumor budding (TB), tumor–stroma ratio, tumor-infiltrating lymphocytes (TIL), “microcystic, elongated, fragmented” (MELF) pattern) were analyzed. For each quantitative parameter, a two-tiered system was developed utilizing systematically determined cutoffs. In MSI tumors, TB (≥3 buds/high-power field) was detected to be an independent prognostic factor for inferior outcomes and lymph node metastases. The finding was confirmed in two validation cohorts. For CN-low tumors, solely WHO grading was independently prognostic with inferior outcomes for high-grade tumors. Therefore, we propose the utilization of TB and WHO-based grading, two tissue-based and easy-to-assess biomarkers, in MSI/CN-low endometrial carcinomas for improved clinical management. ABSTRACT: The molecular characterization of endometrial endometrioid adenocarcinomas has provided major advances in its prognostic stratification. However, risk assessment of microsatellite instability (MSI) and copy-number (CN)-low cases remains a challenge. Thus, we aimed to identify tissue-based morphologic biomarkers that might help in the prognostic stratification of these cases. Histomorphologic parameters (WHO grading, tumor budding (TB), tumor–stroma ratio (as a quantitative description of stromal desmoplasia), tumor-infiltrating lymphocytes (TIL), “microcystic, elongated, fragmented” (MELF) pattern) were analyzed in resection specimens of the TCGA-UCEC cohort (n = 228). For each quantitative parameter, a two-tiered system was developed utilizing systematically determined cutoffs. Associations with survival outcomes were calculated in univariate and multivariate analysis and validated in two independent cohorts. In MSI tumors, only TB remained an independent prognostic factor. TB (≥3 buds/high-power field) was associated with inferior outcomes and with lymph node metastases. The prognostic significance of TB was confirmed in two validation cohorts. For CN-low tumors, established grading defined by the WHO was independently prognostic with inferior outcomes for high-grade tumors. The evaluation of TB might help in identifying MSI-patients with unfavorable prognosis who, e.g., could benefit from lymphadenectomy. WHO-based grading facilitates independent prognostic stratification of CN-low endometrioid adenocarcinomas. Therefore, we propose the utilization of TB and WHO-based grading, two tissue-based and easy-to-assess biomarkers, in MSI/CN-low endometrial carcinomas for improved clinical management. MDPI 2023-07-28 /pmc/articles/PMC10416921/ /pubmed/37568650 http://dx.doi.org/10.3390/cancers15153832 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stögbauer, Fabian
Geß, Barbara
Brambs, Christine
Lautizi, Manuela
Kacprowski, Tim
Ourailidis, Iordanis
Bronger, Holger
Kiechle, Marion
Noske, Aurelia
Keller, Gisela
Jesinghaus, Moritz
Poremba, Christopher
Weichert, Wilko
Boxberg, Melanie
Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients
title Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients
title_full Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients
title_fullStr Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients
title_full_unstemmed Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients
title_short Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients
title_sort independent tissue-based biomarkers in endometrioid endometrial cancer: tumor budding in microsatellite instability and who grading in copy-number-low patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416921/
https://www.ncbi.nlm.nih.gov/pubmed/37568650
http://dx.doi.org/10.3390/cancers15153832
work_keys_str_mv AT stogbauerfabian independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients
AT geßbarbara independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients
AT brambschristine independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients
AT lautizimanuela independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients
AT kacprowskitim independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients
AT ourailidisiordanis independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients
AT brongerholger independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients
AT kiechlemarion independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients
AT noskeaurelia independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients
AT kellergisela independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients
AT jesinghausmoritz independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients
AT porembachristopher independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients
AT weichertwilko independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients
AT boxbergmelanie independenttissuebasedbiomarkersinendometrioidendometrialcancertumorbuddinginmicrosatelliteinstabilityandwhogradingincopynumberlowpatients